4.7 Article

Nose to brain delivery of Astragaloside IV by β-Asarone modified chitosan nanoparticles for multiple sclerosis therapy

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Neurosciences

Exosomes derived from bone marrow mesenchymal stromal cells promote remyelination and reduce neuroinflammation in the demyelinating central nervous system

Jing Zhang et al.

Summary: Injury to OLs results in demyelination, which is often seen in patients with neurodegenerative diseases. MSC-Exo treatment shows promising therapeutic effects on enhancing remyelination in both experimental autoimmune encephalomyelitis (EAE) and cuprizone (CPZ) mouse models of demyelination. Exosomes harvested from MSCs may promote remyelination by acting directly on OPCs and indirectly on microglia, providing a potential treatment for demyelinating and neurodegenerative disorders in the CNS.

EXPERIMENTAL NEUROLOGY (2022)

Article Biophysics

Glial-fibrillary-acidic-protein (GFAP) biomarker detection in serum-matrix: Functionalization strategies and detection by an ultra-high-frequency surface-acoustic-wave (UHF-SAW) lab-on-chip

M. Agostini et al.

Summary: GFAP has attracted attention as a promising biomarker for pathologies affecting the human central nervous system, with potential applications in clinical diagnostics for multiple brain-pathology biomarkers.

BIOSENSORS & BIOELECTRONICS (2021)

Review Neurosciences

Altered astrocytic function in experimental neuroinflammation and multiple sclerosis

Sofia Pereira das Neves et al.

Summary: Multiple sclerosis is a chronic inflammatory disease of the central nervous system that affects about 2.5 million people worldwide. There is currently no cure for MS and the available treatments only slow the initial phases of the disease. Disease progression and disability in MS are better correlated with the maintenance of a persistent low-grade inflammation inside the CNS, driven by local glial cells like astrocytes.
Review Medicine, General & Internal

Current and emerging disease-modulatory therapies and treatment targets for multiple sclerosis

F. Piehl

Summary: Treatment of multiple sclerosis is evolving with the approval of novel and increasingly effective disease-modulatory therapies. In clinical development, inhibitors of Bruton's tyrosine kinase represent a new emerging drug class in MS. Accumulating evidence suggests the importance of early high effective therapy while maintaining acceptable tolerability.

JOURNAL OF INTERNAL MEDICINE (2021)

Article Chemistry, Multidisciplinary

Intranasal delivery of interferon-β-loaded nanoparticles induces control of neuroinflammation in a preclinical model of multiple sclerosis: A promising simple, effective, non-invasive, and low-cost therapy

Luis F. Gonzalez et al.

Summary: A new delivery system of IFN-β nanoparticles via intranasal administration was developed to improve clinical symptoms and control neuroinflammation in an experimental model of multiple sclerosis, showing potential effectiveness, non-invasiveness, and cost-effectiveness as a therapy for MS.

JOURNAL OF CONTROLLED RELEASE (2021)

Article Oncology

β-asarone suppresses HCT116 colon cancer cell proliferation and liver metastasis in part by activating the innate immune system

Min Chen et al.

Summary: Studies have shown that beta-asarone has a powerful inhibitory effect on the proliferation of HCT116 colon cancer cells, potentially through influencing gene expression related to cell cycle, cell division, cell proliferation, and apoptosis. Additionally, beta-asarone may activate the immune system to suppress colon cancer cell proliferation and metastasis in vivo.

ONCOLOGY LETTERS (2021)

Article Pharmacology & Pharmacy

Nose-to-brain delivery of borneol modified tanshinone IIA nanoparticles in prevention of cerebral ischemia/reperfusion injury

Luting Wang et al.

Summary: Bo-TSA-NP is a novel nano-drug delivery system with sustained release and P-gp inhibition properties, which significantly improves the preventive effect on cerebral ischemia/reperfusion injury (CIRI) through intranasal administration.

DRUG DELIVERY (2021)

Article Multidisciplinary Sciences

MAFG-driven astrocytes promote CNS inflammation

Michael A. Wheeler et al.

NATURE (2020)

Article Immunology

Astragaloside IV inhibits astrocyte senescence: implication in Parkinson's disease

Mei-Ling Xia et al.

JOURNAL OF NEUROINFLAMMATION (2020)

Editorial Material Clinical Neurology

Disease-modifying therapy aids cognition in multiple sclerosis

Maria Pia Amato et al.

NATURE REVIEWS NEUROLOGY (2020)

Article Chemistry, Multidisciplinary

Enhanced nose-to-brain delivery of tranilast using liquid crystal formulations

Gerard Lee See et al.

JOURNAL OF CONTROLLED RELEASE (2020)

Article Multidisciplinary Sciences

Anacardic acid induces IL-33 and promotes remyelination in CNS

Asa Ljunggren-Rose et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)

Article Multidisciplinary Sciences

Dynamics of oligodendrocyte generation in multiple sclerosis

Maggie S. Y. Yeung et al.

NATURE (2019)

Article Pharmacology & Pharmacy

Chitosan and chitosan coating nanoparticles for the treatment of brain disease

Shuangwen Yu et al.

INTERNATIONAL JOURNAL OF PHARMACEUTICS (2019)

Article Multidisciplinary Sciences

Neuronal vulnerability and multilineage diversity in multiple sclerosis

Lucas Schirmer et al.

NATURE (2019)

Review Biotechnology & Applied Microbiology

Progressive multiple sclerosis: from pathophysiology to therapeutic strategies

Simon Faissner et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

Review Engineering, Biomedical

Nanomaterial-based blood-brain-barrier (BBB) crossing strategies

Jinbing Xie et al.

BIOMATERIALS (2019)

Article Medicine, General & Internal

Parkinson's Disease

Stephen G. Reich et al.

MEDICAL CLINICS OF NORTH AMERICA (2019)

Review Chemistry, Multidisciplinary

Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs

Mukta Agrawal et al.

JOURNAL OF CONTROLLED RELEASE (2018)

Review Medicine, General & Internal

Multiple sclerosis

Alan J. Thompson et al.

LANCET (2018)

Article Biochemistry & Molecular Biology

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis

Ivan Jelcic et al.

Article Integrative & Complementary Medicine

Anti-Inflammatory and Immunostimulatory Activities of Astragalosides

Yan Qi et al.

AMERICAN JOURNAL OF CHINESE MEDICINE (2017)

Article Medicine, Research & Experimental

β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1

Nanbu Wang et al.

BIOMEDICINE & PHARMACOTHERAPY (2017)

Review Clinical Neurology

Disease-modifying therapies and infectious risks in multiple sclerosis

Alexander Winkelmann et al.

NATURE REVIEWS NEUROLOGY (2016)

Review Chemistry, Multidisciplinary

Chitosan in nasal delivery systems for therapeutic drugs

Luca Casettari et al.

JOURNAL OF CONTROLLED RELEASE (2014)

Article Biochemistry & Molecular Biology

Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation

Lior Mayo et al.

NATURE MEDICINE (2014)

Review Chemistry, Multidisciplinary

pH-Responsive Nanoparticles Shelled with Chitosan for Oral Delivery of Insulin: From Mechanism to Therapeutic Applications

Hsing-Wen Sung et al.

ACCOUNTS OF CHEMICAL RESEARCH (2012)

Review Chemistry, Multidisciplinary

Injectable and biodegradable hydrogels: gelation, biodegradation and biomedical applications

Yulin Li et al.

CHEMICAL SOCIETY REVIEWS (2012)

Article Clinical Neurology

The Parkinson's complex: Parkinsonism is just the tip of the iceberg

JW Langston

ANNALS OF NEUROLOGY (2006)

Article Pharmacology & Pharmacy

Pharmacokinetics of Astragaloside IV in Rats by liquid chromatography coupled with tandem mass spectrometry

Y Du et al.

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2005)